focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Caution prevails in world markets ahead of Fed

Wed, 17th Mar 2021 09:40

* Investors watching for signs of faster policy
normalisation

* Fed statement due at 1800 GMT

* European shares open weaken

* Graphic: Global asset performance http://tmsnrt.rs/2yaDPgn

* Graphic: World FX rates http://tmsnrt.rs/2egbfVh

By Dhara Ranasinghe

LONDON, March 17 (Reuters) - Caution descended on markets on
Wednesday with world stocks holding below recent record highs as
investors waited to see whether the U.S. Federal Reserve would
signal a faster path toward policy normalisation than previously
expected.

The U.S. central bank ends a closely anticipated two-day
meeting later in the day, after a sharp rise in U.S. Treasury
yields this year on expectations for stronger growth and
inflation.

The Fed is expected to forecast that the U.S. economy will
grow in 2021 at the fastest rate in decades. But investors who
expect rosier projections to translate to any change in monetary
policy will probably be disappointed.

"This is one of the most important Fed meetings we've had
for some time and the impact will be felt across asset classes,"
said Seema Shah, chief strategist at Principal Global Investors.

"Markets are hoping for reassurance from the Fed that rising
bond yields are not something to worry about, and that takes a
bit of steam out of the bond market."

Before the Fed statement at 1800 GMT, calm prevailed across
world markets.

MSCI's world equity index was down 0.1%, but
keeping last month's record highs within sight.

European shares were a touch softer ,
while in Asia, an index of regional equities excluding Japan
pulled back 0.4%. Japan's Nikkei 225
closed flat.

There was some good news for AstraZeneca as
Australia's pharmaceutical regulator said the rollout of the
company's COVID-19 vaccine would continue, even though many
European nations have paused vaccinations to investigate
reported side-effects.

U.S. stock futures pointed to a flat open on Wall
Street, after the S&P 500 lost 0.16% on Tuesday.

DOVISH?

Benchmark 10-year Treasury yields were a touch
higher at 1.63%, holding near 13-month highs reached on Friday.
They have risen 72 basis points so far this year. That compares
with a 24 bps increase in German peers and a 7 bps
rise in Japanese borrowing costs.

Inflation expectations have also ticked higher with the
break-even rate on 10-year Treasury Inflation-Protected
Securities (TIPS) on Tuesday rising above 2.3% for
the first time since July 2014. The break-even rate for 30-year
TIPS hit 2.24%, the highest since September 2014.

"We expect (Fed Chair Jerome) Powell to note the FOMC has
the tools to intervene if the bond market becomes disorderly or
constrains the economic recovery," analysts at Commonwealth Bank
of Australia wrote.

"But we expect Powell to push back against talk of policy
tightening because of the large amount of labour market slack
... U.S. bond yields and the U.S. dollar could jump if the
FOMC’s post-meeting statement and Powell’s statement are not
deemed dovish enough."

An index tracking the dollar against six major peers
was around 91.92. The euro was weaker on the day at $1.1892
. The dollar was up about 0.1% at 109.13 yen.

Currency market caution may extend all week, with the Bank
of England meeting on Thursday and the Bank of Japan wrapping up
a policy review on Friday, in which it may phase out a numerical
target for its asset buying.

Elsewhere, oil prices slipped for a fourth day as concern
about weaker demand in Europe outweighed an industry report that
showed U.S. crude stockpiles unexpectedly fell last week.

Brent crude futures fell 27 cents to $68.12 a barrel
and U.S. crude futures slipped 14 cents to $64.65.

For Reuters Live Markets blog on European and UK stock
markets, please click on:

(Reporting by Dhara Ranasinghe; Additional reporting by Kevin
Buckland in Tokyo; editing by Larry King)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.